India's Senores Pharma rises on acquisition of rights to sell Roflumilast

Senores Pharmaceuticals

21/02/2025 04:35

** Shares of Senores Pharmaceuticals Ltd  SENO.NS  rise as
much as 5.8% to 565 rupees 
    ** Co via its unit acquires USFDA-approved abbreviated new
drug application (ANDA) for Roflumilast 250 mcg, 500 mcg tablets
used to treat flare-ups in people with severe chronic
obstructive pulmonary disease 
    ** Adds, acquisition will be funded through initial public
offer proceeds
    ** Stock on track to gain for 3rd straight day
    ** SENO last up 4%, cutting YTD losses to 6.1%

 (Reporting by Meenakshi Maidas in Bengaluru)
 ((meenakshi.maidas@thomsonreuters.com;))